文献速递乳腺癌

MANTA 2期试验:氟维司群联合Vistusertib对比依维莫司或单药治疗HR阳性转移性乳腺癌

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2019-01-01

MANTA 2期随机试验纳入333例芳香化酶抑制剂治疗后进展的ER阳性晚期/转移性乳腺癌绝经后女性,按2:3:3:2随机接受氟维司群单药、联合每日或间歇Vistusertib、或联合依维莫司。主要终点PFS:依维莫司组12.3个月显著优于Vistusertib组和单药组;Vistusertib每日或间歇联合与单药相比无显著PFS差异。

要点

  • 氟维司群联合依维莫司组中位PFS达12.3个月,优于Vistusertib组和单药组。
  • Vistusertib每日或间歇联合氟维司群与单药相比PFS无显著差异。
  • 双mTORC1/mTORC2抑制剂Vistusertib未在联合氟维司群中显示获益。

核心结论

  • 氟维司群联合依维莫司较联合Vistusertib或单药显著延长PFS。
  • 联合双mTORC1/mTORC2抑制剂Vistusertib未能显示获益。

研究设计与样本

  • MANTA为开放标签、2期随机临床试验,2014年4月1日至2016年10月24日在9国88个中心开展。
  • 共333例ER阳性、既往芳香化酶抑制剂治疗后进展的乳腺癌患者按2:3:3:2随机分组。
  • 分组:氟维司群67例、联合每日Vistusertib 103例、联合间歇Vistusertib 98例、联合依维莫司65例。
  • 分析基于意向性治疗人群。

主要发现

  • 中位PFS:氟维司群单药5.4个月(95%CI 3.5-9.2),联合每日Vistusertib 7.6个月(95%CI 5.9-9.4)。
  • 中位PFS:联合间歇Vistusertib 8.0个月(95%CI 5.6-9.9),联合依维莫司12.3个月(95%CI 7.7-15.7)。
  • 每日Vistusertib联合组与单药组PFS无显著差异(HR 0.88,95%CI 0.63-1.24;P=.46)。
  • 间歇Vistusertib联合组与单药组PFS无显著差异(HR 0.79,95%CI 0.55-1.12;P=.16)。

临床怎么用

  • 对于芳香化酶抑制剂治疗后进展的ER阳性转移性乳腺癌,氟维司群联合依维莫司显示PFS获益。
  • 不推荐在氟维司群基础上联合Vistusertib(每日或间歇方案)用于该类患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Randomized clinical trials have demonstrated a substantial benefit of adding everolimus to endocrine therapy. Everolimus inhibits the mammalian target of rapamycin complex 1 (mTORC1) complex but not mTORC2, which can set off an activating feedback loop via mTORC2. Vistusertib, a dual inhibitor of mTORC1 and mTORC2, has demonstrated broad activity in preclinical breast cancer models, showing superior activity to everolimus. OBJECTIVE: To evaluate the safety and efficacy of vistusertib in combination with fulvestrant compared with fulvestrant alone or fulvestrant plus everolimus in postmenopausal women with estrogen receptor-positive advanced or metastatic breast cancer. DESIGN, SETTING, AND PARTICIPANTS: The MANTA trial is an open-label, phase 2 randomized clinical trial in which 333 patients with estrogen receptor-positive breast cancer progressing after prior aromatase inhibitor treatment underwent randomization (2:3:3:2) between April 1, 2014, and October 24, 2016, at 88 sites in 9 countries: 67 patients were assigned to receive fulvestrant, 103 fulvestrant plus vistusertib daily, 98 fulvestrant plus vistusertib intermittently, and 65 fulvestrant plus everolimus. Treatment was continued until disease progression, development of unacceptable toxic effects, or withdrawal of consent. Analysis was performed on an intention-to-treat basis. INTERVENTIONS: Fulvestrant alone or in combination with vistusertib (continuous or intermittent dosing schedules) or everolimus. MAIN OUTCOMES AND MEASURES: The primary end point was progression-free survival (PFS). RESULTS: Among the 333 women in the study (median age, 63 years [range, 56-70 years]), median PFS was 5.4 months (95% CI, 3.5-9.2 months) with fulvestrant, 7.6 months (95% CI, 5.9-9.4 months) with fulvestrant plus daily vistusertib, 8.0 months (95% CI, 5.6-9.9 months) with fulvestrant plus intermittent vistusertib, and 12.3 months (95% CI, 7.7-15.7 months) with fulvestrant plus everolimus. There was no significant difference in PFS between those receiving fulvestrant plus daily or intermittent vistusertib and fulvestrant alone (hazard ratio, 0.88 [95% CI, 0.63-1.24]; P = .46; and hazard ratio, 0.79 [95% CI, 0.55-1.12]; P = .16). CONCLUSIONS AND RELEVANCE: The combination of fulvestrant plus everolimus demonstrated significantly longer PFS compared with fulvestrant plus vistusertib or fulvestrant alone. The trial failed to demonstrate a benefit of adding the dual mTORC1 and mTORC2 inhibitor vistusertib to fulvestrant. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02216786 and EudraCT number: 2013-002403-34.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Schmid P, Zaiss M, Harper-Wynne C, et al. Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 31465093. doi:10.1001/jamaoncol.2019.2526

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。